In 2016, results of an extensive trial broadened the range of malignancies that can be treated with everolimus to include neuroendocrine tumours (NETs) of the lung and gastrointestinal tract. Furthermore, studies aimed at identifying biomarkers with increased specificity, and at better defining high-grade NETs have enabled substantial progress towards delivering effective targeted treatments to patients with NETs.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Prognostic value of CT-based radiomics in grade 1–2 pancreatic neuroendocrine tumors
Cancer Imaging Open Access 23 February 2024
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yao, J. C. et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 387, 968–977 (2016).
Yao, J. C. et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 514–523 (2011).
Bosman, F. T., Carneiro, F., Hruban, R. H. & Theise, N. D. WHO Classification of Tumours of the Digestive System Vol. 3 (IARC, 2010).
Tang, L. H. et al. Well-differentiated neuroendocrine tumors with a morphologically apparent high-grade component: a pathway distinct from poorly differentiated neuroendocrine carcinomas. Clin. Cancer Res. 22, 1011–1017 (2016).
Tang, L. H., Basturk, O., Sue, J. J. & Klimstra, D. S. A practical approach to the classification of WHO grade 3 (G3) well-differentiated neuroendocrine tumor (WD-NET) and poorly differentiated neuroendocrine carcinoma (PD-NEC) of the pancreas. Am. J. Surg. Pathol. 40, 1192–1202 (2016).
Strosberg, J. et al. NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-Dotatate: efficacy, safety, QOL results and subgroups analysis [abstract]. Ann. Oncol. 27 (Suppl. 6), vi136–vi148 (2016).
Bodei, L. et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging 43, 839–851 (2016).
Khan, M. S. et al. Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms. Clin. Cancer Res. 22, 79–85 (2016).
Acknowledgements
The authors would like to thank L. Zampaglione for her assistance with manuscript editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Falconi, M., Partelli, S. Defining rules for increasingly personalized treatments. Nat Rev Clin Oncol 14, 80–82 (2017). https://doi.org/10.1038/nrclinonc.2016.197
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2016.197
This article is cited by
-
Prognostic value of CT-based radiomics in grade 1–2 pancreatic neuroendocrine tumors
Cancer Imaging (2024)
-
Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance
European Journal of Nuclear Medicine and Molecular Imaging (2021)